Elevated MR-proANP plasma concentrations are associated with sepsis and predict mortality in critically ill patients

Eray Yagmur1*, Johanna Hermine Sckaer2, Ger H. Koek3, Ralf Weiskirchen4*, Christian Trautwein2, Alexander Koch2† and Frank Tacke2,5†

Abstract

Background and aims: Mid-regional pro atrial natriuretic peptide (MR-proANP) is an established biomarker for heart failure, based on its key role in regulating homeostasis of water balance and blood pressure. The aim of the study was to determine the value of MR-proANP as a clinical biomarker in critical illness and/or sepsis. Upon admission to the medical intensive care unit (ICU), we investigated MR-proANP plasma concentrations in 217 critically ill patients (144 with sepsis, 73 without sepsis). Results were compared with 65 healthy controls.

Results: MR-proANP plasma levels were significantly elevated in critically ill patients, when compared to healthy controls. Notably, MR-proANP levels were significantly higher in ICU patients with sepsis. MR-proANP levels were not associated with metabolic comorbidities like diabetes or obesity. In critically ill patients, MR-proANP plasma concentrations correlated with inflammatory cytokines, markers of organ dysfunction and several adipocytokines, such as resistin, retinol-binding protein 4 (RBP4) and adiponectin. Importantly, high MR-proANP plasma levels were associated with mortality, as MR-proANP levels above 227.0 pmol/l indicated a particularly increased mortality risk in ICU patients. The association between MR-proANP and mortality was independent of single organ failure and inflammation markers.

Conclusion: Our study emphasizes the role of circulating MR-proANP as a biomarker in critically ill patients, in which high MR-proANP indicates organ dysfunction, sepsis and mortality risk. The association between high MR-proANP and inflammatory as well as adipose tissue-derived endocrine mediators warrants further pathophysiological investigations.

Keywords: MR-proANP, Mid-regional pro atrial natriuretic peptide, ICU, Critical illness, Sepsis, Inflammation, Metabolism, Adipocytokines, Diabetes, Obesity

Background

The natriuretic peptides of type A, B and C (ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; CNP, C-type natriuretic peptide) belong to a family of cardio- and vascular-derived hormones. They exert diuretic, natriuretic and hypotensive actions and protect the organism from excessive fluid and high blood pressure. Through a variety of effects on vascular tone, intravascular volume and redistribution, cardiovascular remodelling and energy metabolism, natriuretic peptides play a key role in maintaining cardiovascular homeostasis, water balance and blood pressure [1–4]. In this context, atrial natriuretic peptides (ANP) are predominantly expressed in the right atrium of the heart and secreted during an atrial distension such as in cardiac dysfunction or heart

*Correspondence: eyagmur@ukaachen.de
†Alexander Koch and Frank Tacke contributed equally to this work
1 Medical Care Center, Dr. Stein and Colleagues, Tomphereke 45, 41169 Mönchengladbach, Germany
Full list of author information is available at the end of the article

© The Author(s) 2019. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
of pro-inflammatory markers are observed. In line, recent data suggest that ANP regulates inflammatory processes such as macrophage function, priming of neutrophils and the expression of pro-inflammatory markers [20, 21]. Thus, ANP also participates in innate immune reactions [2, 22]. Moreover, activation of intracellular cGMP induces lipolysis and mobilization of free fatty acids in human adipocytes [23, 24]. This demonstrates the interaction of ANP with white and brown adipose tissue. Specifically, ANP increases the expression and secretion of adiponectin, an adipokine with insulin-sensitizing properties, as observed in primary human adipocyte cultures, healthy subjects and patients with congestive heart failure [23, 25, 26]. In addition, the ANP/cGMP signalling pathway increases β-cell mass and insulin secretion in the pancreas [23]. With regard to ANP removal, it has been clearly shown that upregulation of NPR-C is associated with metabolic alterations such as obesity and obesity-related metabolic disorders like type 2 diabetes and metabolic syndrome [23, 27].

Based on this wide range of physiological functions of ANP and its associated alterations, ANP has been linked to inflammatory responses and metabolic alterations that occur during critical illness [9, 28, 29]. Critical illness and MR-proANP are associated with and affected by alterations in secretory and metabolic functions of adipose tissue [30, 31]. In different cohorts of ICU patients, high MR-proANP plasma levels have been associated with disease severity and outcome of critical illness [8, 11]. In addition, elevated MR-proANP levels are described to be diagnostic for sepsis after burn injury [32]. In this study, we investigated the clinical and prognostic relevance of MR-proANP plasma levels in a large cohort of critically ill patients from a medical ICU including sepsis, pre-existing diabetes, obesity and organ dysfunction.

**Methods**

**Study design and patient characteristics**

Critically ill patients were included at admission to the medical ICU at the RWTH University Hospital Aachen, Germany. Patients, who were admitted for post-interventional observational stay or underwent an elective procedure, were excluded [33]. The cohort consisted of 217 critically ill patients (144 with sepsis, 73 without sepsis). Patients’ characteristics are shown in Table 1. The patients were categorized as sepsis and non-sepsis according to the Third International Consensus Definitions for Sepsis and Septic Shock (sepsis-3) [34], and were treated following the current guidelines for treatment of sepsis (Surviving Sepsis Campaign) [35]. Underlying disease etiologies of sepsis and non-sepsis patients are shown in Table 2. A control group, we analysed healthy blood donors with normal blood counts, normal values of liver enzymes, glomerular
filtration rates, serum creatinine and C-reactive protein (CRP) concentration [36]. All healthy subjects had a negative serology for human immunodeficiency virus (HIV) [36]. In order to determine long-term outcome, we contacted the patients, their relatives and/or the general practitioner in approximately 6-months intervals after discharge from the hospital over a period of 3 years [36].

**Measurements of MR-proANP plasma levels**

Before therapeutic interventions, blood samples were collected upon admission to the ICU, centrifuged, and plasma was stored at −80 °C. Plasma MR-proANP concentrations (epitopes covering amino acids 53–90, equivalent to NT-proANP and active ANP [10] were determined using an automated immunofluorescent assay based on TRACE technology (Time-resolved Amplified Cryptate Emission, B.R.A.H.M.S Kryptor compact, Hennigsdorf, Germany), according to manufacturer’s instructions (MR-proANP Kryptor, #819.050, B.R.A.H.M.S, Hennigsdorf, Germany). Measurements of the adipocytokines and related proteins leptin, retinol-binding protein 4 (RBP4), adiponectin, ghrelin, and resistin were included, as previously reported [37–41]. In addition, soluble urokinase-type plasminogen activator receptor (suPAR) and amino-terminal pro C-type natriuretic peptide (NT-proCNP) concentrations as markers of disease severity and inflammatory response were also investigated as described previously [36, 42].

**Statistical analysis**

Owing to the skewed distribution of the parameters, data are given as median and range, and shown

| Parameter                              | All patients | Non-sepsis | Sepsis |
|----------------------------------------|--------------|------------|--------|
| Number                                 | 217          | 73         | 144    |
| Sex (male/female)                      | 133/84       | 48/25      | 85/59  |
| Age median (range) [years]             | 64 (18–90)   | 61 (18–85) | 65 (20–90) |
| APACHE-II score median (range)         | 18 (2–43)    | 13.5 (2–33) | 19 (4–43) |
| SOFA score median (range)              | 9 (0–19)     | 7.0 (0–17) | 9.5 (2–19) |
| SAPS2 score median (range)             | 41 (0–73)    | 41.0 (13–72) | 40.5 (0–73) |
| ICU days median (range)                | 7 (1–137)    | 6 (1–45)   | 9 (1–137) |
| Death during ICU n(%)                  | 46 (21.2%)   | 9 (12.3%)  | 37 (25.7%) |
| Death overall (total) n(%)              | 86 (39.6%)   | 22 (30.1%) | 64 (44.4%) |
| Mechanical ventilation n(%)            | 144 (66.4%)  | 46 (63%)   | 98 (67%) |
| Preexisting diabetes n(%)              | 65 (30.0%)   | 22 (30.1%) | 43 (29.9%) |
| BMI median (range) [m²/kg]              | 26.0 (15.3–86.5) | 25.7 (15.9–40.5) | 26.0 (15.3–86.5) |
| WBC median (range) [×10³/µl]           | 12.9 (0.1–208) | 12.5 (1.8–29.6) | 13.8 (0.1–208) |
| CRP median (range) [mg/dl]              | 103.0 (5–230) | 17 (5–230)  | 163.5 (5–230) |
| IL-6 median (range) [pg/ml]            | 145.0 (2–28,000) | 66.5 (1.5–5000) | 240 (2–28,000) |
| Procalcitonin median (range) [pmol/l]   | 0.2 (0.03–100) | 1.8 (0.03–207.5) |
| Creatinine median (range) [mg/dl]       | 1.3 (0.1–15)  | 1.0 (0.2–15) | 1.6 (0.1–10.7) |
| INR median (range)                      | 1.16 (0.92–1.3) | 1.17 (0.95–6.73) | 1.16 (0.92–13) |
| MR-proANP day 1 median (range) [pmol/l] | 214.0 (2.1–3417.0) | 147.2 (2.1–1625.0) | 246.6 (7.8–3417.0) |

For quantitative variables, median and range (in parenthesis) are given.
graphically by box-and-whiskers plots. The degree of association between two variables was assessed by the Spearman rank correlation test. Comparisons of parameters between two different groups were conducted with the Mann–Whitney U-test. All values, including outside values as well as far out values, were included. P-values less than 0.05 were considered as statistically significant. Receiver operating characteristic (ROC) curve analysis was carried out to determine the diagnostic sensitivity and specificity of MR-proANP in critically ill patients. The ROC curve analysis and the derived area under the curve (AUC) statistic provide a global and standardized appreciation of the accuracy of a marker or a composite score for predicting an event. ROC curves were generated by plotting sensitivity against 1-specificity [42]. The prognostic value of the variables was tested by univariate and multivariate analyses in the Cox regression model. Survival curves were generated by Kaplan–Meier analyses with an MR-proANP cut-off level calculated via the Youden Index [42]. All analyses were performed with IBM SPSS Statistics (SPSS; Chicago, IL, USA).

**Results**

**MR-proANP plasma levels are significantly elevated in critically ill patients as compared with healthy controls**

Based on the wide range of physiological functions of ANP and its associated alterations, ANP has been linked to both inflammatory and metabolic responses that typically occur during critical illness [9, 28, 29]. In our study, we found that MR-proANP plasma levels were significantly elevated in a large cohort of 217 critically ill patients (median 214.0 pmol/l, range 2.1–3417.0 pmol/l; Table 1) at admission to the ICU as compared with 65 healthy controls (median 18.5 pmol/l, range 3.5–61.7 pmol/l, p < 0.001; Fig. 1).

**MR-proANP plasma levels are particularly elevated in critically ill patients with sepsis**

High MR-proANP plasma levels in critically ill patients had been previously reported to be associated with sepsis [8, 11]. Within our cohort of 217 critically ill patients, 144 fulfilled sepsis criteria, while 73 were admitted to the ICU due to other causes of critical illness (Table 2). Plasma concentrations of MR-proANP were significantly elevated in patients with sepsis (median 246.6 pmol/l, range 7.8–3417.0 pmol/l) as compared to ICU patients without sepsis (median 147.2 pmol/l, range 2.1–1625.0 pmol/l, p < 0.001; Fig. 2a and Table 2). We analysed the diagnostic value of MR-proANP for sepsis in comparison to classical markers of inflammation and bacterial infection by using ROC curve analyses. Whereas CRP achieved AUC statistics of 0.847 and white blood cell count of 0.585, MR-proANP only reached an AUC of 0.656 (Fig. 2b).

Among the septic or non-septic critically ill patients, there was no association between MR-proANP plasma concentrations and different disease etiologies leading to ICU admission (data not shown).

**MR-proANP levels in critically ill patients are closely correlated to biomarkers of inflammation, organ dysfunction and clinical scores**

Mice lacking a functional NPR 1 gene encoding NPR-A exhibit hypertension and marked cardiac hypertrophy with interstitial fibrosis, in association with enhanced activation of pro-inflammatory cytokines, probably via...
MR-proANP (pmol/l)

- no sepsis (n=73)
- yes sepsis (n=144)

MR-proANP vs suPAR (ng/ml)

- r=0.493
- p<0.001

MR-proANP vs NT-proCNP (pmol/l)

- r=0.683
- p<0.001

MR-proANP (pmol/l)

- ≤ 10 APACHE-II score (n=49)
- > 10 APACHE-II score (n=146)

p=0.004

MR-proANP vs CRP

sensitivity

1 - specificity
nuclear factor kappa mediated signalling pathway [43, 44]. To determine the factors possibly promoting elevated MR-proANP plasma levels in critically ill patients, correlation analyses with extensive sets of laboratory parameters were performed. At admission to the ICU, plasma MR-proANP concentrations in the total cohort and the subgroups of sepsis and non-sepsis patients were closely correlated with classical markers of inflammation and bacterial infection, such as C-reactive protein \((r = 0.286, p < 0.001)\), procalcitonin \((r = 0.378, p < 0.001)\), and experimental markers of inflammation such as soluble urokinase plasminogen activator receptor (suPAR, \(r = 0.493, p < 0.001\), Fig. 2c), and NT-proCNP \((r = 0.683, p < 0.001\), Fig. 2d, Table 3).

With regard to organ function, we could reveal strong associations with renal and hepatic function for the total study cohort and the subgroups of sepsis and non-sepsis patients. Specifically, we could demonstrate an inverse association with renal function as displayed by a highly significant correlations with the glomerular filtration rate of cystatin C \((r = −0.675, p < 0.001)\), cystatin C \((r = 0.675, p < 0.001)\), creatinine \((r = 0.629, p < 0.001)\) and urea \((r = 0.623, p < 0.001)\) serum concentrations (Table 3), indicating renal clearance of MR-proANP [45]. Interestingly, MR-proANP levels inversely correlated with parameters reflecting the liver's biosynthetic and functional capacity, namely albumin \((r = −0.190, p = 0.045)\), pseudocholinesterase activity \((r = −0.339, p < 0.001)\), antithrombin III \((r = −0.216, p = 0.015)\), glutamate dehydrogenase \((r = −0.151, p = 0.037)\) and alanine aminotransferase \((r = −0.172, p = 0.012)\) (Table 3). MR-proANP levels also correlated with the amino-terminal brain natriuretic peptide (NT-proBNP) (Table 3).

Increased MR-proANP levels have been associated with adverse clinical outcome [46]. In fact, MR-proANP plasma levels correlated positively with established clinical disease severity scores (Table 3). Moreover, critically ill patients with a high (acute physiology and chronic health II (APACHE-II) score above 10 showed significantly higher MR-proANP levels at ICU admission (median 239.7 pmol/l, range 2.1–1871.0 pmol/l) in comparison to ICU patients admitted with an APACHE-II score of 10 or less (median 143.0 pmol/l, range 2.1–3417.0 pmol/l, \(p = 0.004\), Fig. 2e).

For the total cohort of critically ill patients a strong association of MR-proANP plasma concentrations and established clinical scores like sequential organ failure assessment (SOFA; \(r = 0.223, p = 0.011\)), simplified acute physiology score 2 (SAPS2; \(r = 0.341, p = 0.006\)), and acute physiology and chronic health II (APACHE II; \(r = 0.260, p < 0.001\)) scores could be shown, corroborating that MR-proANP levels are closely linked to disease severity in critical illness (Table 3).

### Table 3 Correlations with MR-proANP plasma concentrations at ICU admission

| Parameters                                      | ICU patients |
|------------------------------------------------|--------------|
| Disease severity/clinical scoring/therapy       |              |
| APACHE II                                      | 0.260        | <0.001 |
| SOFA                                           | 0.223        | 0.011  |
| SAPS                                           | 0.341        | 0.006  |
| Fluid substitution                              | −0.233       | 0.001  |
| Markers of inflammation                        |              |
| White blood cell count                         | −0.148       | 0.029  |
| C-reactive protein                             | 0.286        | <0.001 |
| Procalcitonin                                  | 0.378        | <0.001 |
| suPAR                                          | 0.493        | <0.001 |
| NT-proCNP                                      | 0.683        | <0.001 |
| Markers of organ function                      |              |
| NT-proBNP                                      | 0.740        | <0.001 |
| Urea                                           | 0.623        | <0.001 |
| Creatinine                                     | 0.629        | <0.001 |
| GFR-cystatin C                                 | −0.675       | <0.001 |
| Cystatin C                                     | 0.675        | <0.001 |
| Lipase                                         | −0.191       | 0.012  |
| Pancreatic amylase                             | −0.317       | 0.006  |
| Alamine aminotransferase                       | −0.172       | 0.012  |
| Glutamate dehydrogenase                        | −0.151       | 0.037  |
| Pseudocholinesterase activity                  | −0.339       | <0.001 |
| Albumin                                        | −0.190       | 0.045  |
| Total protein                                  | −0.263       | <0.001 |
| INR                                            | 0.207        | 0.003  |
| aPTT                                           | 0.324        | <0.001 |
| Antithrombin III                               | −0.216       | 0.015  |
| Adipocytokines/metabolic markers               |              |
| Adiponectin                                    | 0.434        | 0.001  |
| Resistin                                       | 0.349        | 0.008  |
| RBP4                                          | 0.306        | 0.012  |
| HOMA-β                                         | 0.332        | 0.007  |
| Parathyroid hormone                            | 0.299        | 0.014  |
| Calcium                                        | −0.288       | <0.001 |
| Phosphorus                                     | 0.241        | 0.001  |

Spearman rank correlation test, only significant results are shown

Measures of hemodynamic instability such as need for volume substitution and vasopressor therapy showed a significant inverse correlation of fluid therapy with plasma MR-proANP levels \((r = −0.233, p = 0.001)\), but not with vasopressor administration (Table 3).

**MR-proANP plasma levels in critically ill patients are not associated with diabetes and obesity**

Prior studies have shown an inverse association with natriuretic peptides and metabolic syndrome, fasting glucose, insulin resistance and diabetes development...
We therefore assessed whether metabolic comorbidities, specifically pre-existing obesity or diabetes, might have an influence on MR-proANP levels also in patients with critical illness. However, neither pre-existing type 2 diabetes \((n=65, \text{median } 226.6 \text{ pmol/l, range } 2.1-1871.0 \text{ pmol/l, } p=0.196; \text{Fig. 3a})\) nor obesity \((n=36, \text{median } 248.1 \text{ pmol/l, range } 17.5-1319.0 \text{ pmol/l, } p=0.126; \text{Fig. 3b})\), as defined by a body mass index (BMI) above 30 kg/m\(^2\), were associated with MR-proANP plasma concentrations. Moreover, by Spearman rank correlation analysis, no correlation between MR-proANP and serum glucose levels, glycosylated hemoglobin A1c (HbA1c) or BMI was present (data not shown). In addition, MR-proANP did not show any correlations with other key markers of glucose metabolism, such as insulin, C-peptide or the homeostasis model assessment-insulin resistance (HOMA-IR) in ICU patients (data not shown). However, β-cell function (HOMA-β) correlated with MR-proANP \((r=3.332, p=0.007, \text{Table 3})\).

Adipose tissue inflammation attributes to dysregulated production and release of inflammatory cytokines and adipocytokines, including interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) as well as leptin, resistin and adiponectin [48]. We investigated the potential

![Fig. 3](image-url)

\(\text{Fig. 3} \ MR\text{-proANP levels are not related to metabolic comorbidities} \ a-\text{b} \ MR\text{-proANP plasma concentrations in ICU patients are neither associated with pre-existing type 2 diabetes} \ a \text{nor obesity, as defined by a body-mass index (BMI) above } 30 \text{ kg/m}^2 \text{.} \ b-\text{d} \ We \text{ observed significant correlations between MR-proANP and several adipocytokines including resistin} \ (c) \text{and adiponectin} \ (d) \text{.} \ p\text{-values (U-test or Spearman rank correlation) are given}\)
association between MR-proANP and adipocytokine responses in critically ill patients. In agreement with the proposed pro-inflammatory association of MR-proANP, we observed significant correlations between MR-proANP and a broad range of adipocytokines including resistin (r = 0.349, p = 0.008, Fig. 3c), adiponectin (r = 0.434, p = 0.001, Fig. 3d), and RBP4 (r = 0.306, p = 0.012, Table 3).

**Elevated MR-proANP plasma levels are associated with mortality in critically ill patients**

Circulating natriuretic peptides like NT-proCNP have been previously suggested as biomarkers for disease severity as well as short- and long-term survival in various conditions of critical illness [42]. We assessed long-term survival in 206 out of 217 patients by contacting the patients, their relatives or their general practitioner during the first three years after ICU discharge. MR-proANP levels at ICU admission were significantly elevated in patients that subsequently died (n = 86, median 309.0, range 2.1–3417.0) compared with survivors (n = 120, median 171.1, range 2.1–1625.0; p < 0.001, Fig. 4a).

By univariate analysis, including markers of inflammation/infection (CRP, p = 0.111; lactate, p = 0.198), hepatic (bilirubin, p = 0.161) and renal (creatinine, p = 0.427) function at admission were not significantly associated with mortality, while MR-proANP showed highest prognostic value (p = 0.013) for ICU mortality. In multivariate Cox regression analyses (including the above mentioned parameters in the model) MR-proANP remained an independent and the only significant prognostic parameter (p = 0.012) to predict overall ICU mortality. In this respect, MR-proANP levels showed comparable prognostic accuracy like established multifactorial scores such as APACHE II (AUC = 0.654 for MR-proANP, 0.638 for APACHE II score changes in ROC analyses). This finding was corroborated by Kaplan–Meier survival curve analyses, demonstrating that patients with MR-proANP plasma levels of the lower quartile (< 25%, corresponding to 91.3 pmol/l) had the best survival rates, while patients with admission MR-proANP levels of the upper quartile (> 75%, corresponding to 506.6 pmol/l) had the highest long-term mortality (Fig. 4b). Using the calculated optimal cut-off for MR-proANP of 227.0 pmol/l, patients with high MR-proANP demonstrated a high mortality rate, as depicted by Kaplan–Meier survival curve analysis (Fig. 4c).

**Discussion**

The expression and secretion of the atrial natriuretic polypeptide (ANP) hormone has been mainly studied in the context of cardiac diseases [49]. In particular, increases in ANP or MR-proANP concentrations in blood circulation were often considered to be dependent on the prevalence of cardiac insufficiency and classical cardiac risk factors such as diabetes and renal failure [50]. Furthermore, ANP has been linked to both inflammatory and metabolic responses that typically occur during critical illness [9, 28, 29].

However, ANP is expressed and secreted by the cells of the heart atria and BNP, mainly in the ventricles that is therefore less sensitive to intraventricular pressure increase and hemodynamic stress than BNP. NT-proBNP is currently recognized as the clinical gold standard for the diagnosis of acute destabilized heart failure in patients with dyspnea [51]. In critically ill patients, elevated plasma concentrations of natriuretic peptides are found in severe hemodynamic disturbances such as cardiogenic or septic shock due to ventricular dysfunction and the release of proinflammatory cytokines [5, 9]. In accordance to the positive correlation between MR-proANP and NT-proBNP in our study, dramatically increased proinflammatory cytokines in critically ill patients may also contribute to ANP and BNP secretion from the heart.

In our study, we demonstrated that MR-proANP is elevated in critically ill patients already at admission to the ICU as compared with healthy controls, in agreement with prior studies [8, 11, 32]. Moreover, using correlation analyses our study revealed significant associations between MR-proANP and established biomarkers reflecting inflammation, metabolic alterations, and organ dysfunction in medical ICU patients.

Although MR-proANP levels were further elevated in critically ill patients with sepsis, their diagnostic power for sepsis was inferior to routinely used inflammatory markers such as CRP or procalcitonin. In line with our findings, it has been reported that MR-proANP is neither a direct sepsis marker nor a predictor of bacteraemia [32, 52, 53]. Interestingly, in ventilator-associated pneumonia and lower respiratory tract infections, implementing MR-proANP improved survival prediction of clinical severity scores, especially when used in combination with procalcitonin (PCT) [54, 55]. In septic shock patients, MR-proANP was significantly associated with 28-day mortality [56]. Moreover, MR-proANP was associated with cardiorenal dysfunction and an increased risk of terminal kidney disease and mortality [57]. In this context, MR-proANP showed a high accuracy for predicting survival in critical ill patients in our study.

Several studies have shown that obese individuals display lower circulating natriuretic peptide concentrations, indicating that obesity or BMI may be confounding factors for clinical and prognostic utility of MR-proANP.
[58–60]. In our cohort, we found that MR-proANP is strongly correlated with adipocytokines such as adiponectin, RBP4 and resistin, which are important mediators of insulin resistance and metabolic alterations [36, 42]. Interestingly, MR-proANP did only correlate with markers reflecting adipose tissue inflammation, but not with patient’s BMI or pre-existing obesity. Critically ill patients show dramatic metabolic and inflammatory dysfunctions, including dysregulated adipocytokines [30, 31]. Within this context, ANP-binding to the natriuretic peptide receptor A activates the cyclic guanylyl monophosphate (cGMP) to mediate a variety of systemic effects such as lipolysis and free fatty acid mobilization in human adipocytes [19, 23, 24], which may provoke adipocytokine secretion from adipose tissue. The effects of ANP on adipose tissue might sustain inflammatory

---

Fig. 4  MR-proANP is a biomarker for mortality in critically ill patients.  

- **a** Patients that died during or after ICU treatment displayed significant higher MR-proANP levels at ICU admission compared to patients that survived in the long-term follow-up.  
- **b** High vs. low MR-proANP plasma concentrations discriminated survival of the critically ill patients, as displayed by Kaplan–Meier survival curve analysis for MR-proANP separated into quartiles.  
- **c** Elevated MR-proANP plasma concentrations at ICU admission (optimal cut-off: 227.0 pmol/l) predicted the overall mortality in critically ill patients. p-values (U-test or log rank test) are given.
responses, possibly supporting systemic inflammation in critical illness and sepsis. Our findings demonstrate the potential diagnostic and prognostic value of MR-proANP in critically ill patients with sepsis and may contribute to implement MR-proANP as a potential novel biomarker in critical disease.

Conclusion
Our study emphasizes the role of circulating MR-proANP as a potential novel biomarker in critically ill patients, in which high MR-proANP plasma concentrations indicate organ dysfunction, sepsis, disease severity and mortality risk. The association between high MR-proANP and inflammatory as well as adipose tissue-derived endocrine mediators warrants further pathophysiological investigations. Knowledge of these interactions will enhance the understanding of the pathogenic role of natriuretic peptides in critical illness.

Abbreviations
ANP: atrial natriuretic peptide; APACHE: acute physiology and chronic health evaluation; BMI: body mass index; BNP: brain natriuretic peptide; cGMP: cyclic guanyl monophosphate; CNP: C-type natriuretic peptide; GFR glomerular filtration rate; HBcAg: glycosylated hemoglobin A1c; HIV: human immunodeficiency virus; HOMA-β: homeostasis model assessment-β-cell function; HOMA-IR: homeostasis model assessment-insulin resistance; ICU: intensive care unit; IL-6: interleukin 6; INR: international normalized ratio; MR: mid-regional; NPR: natriuretic peptide receptor; NT: amino-terminal; PCT: procalcitonin; RBP4: retinol-binding protein 4; SAPS: simplified acute physiology score; SOFA: sepsis-related organ failure assessment; suPAR: soluble urokinase-type plasminogen activator receptor; TRACE: time-resolved amplified cryptate emission; TNF-α: tumor necrosis factor-α; WBC: white blood cell count.

Acknowledgements
Not applicable.

Authors’ contributions
EY and AK conceived the idea and designed the study together with FT. JHS collected the blood samples and contributed to editing the manuscript. AK, FT and EY analysed and interpreted the clinical and laboratory data and edited the final manuscript. EY performed the MR-proANP measurements and was a major contributor in writing the manuscript. GHK and RW took part in designing the study and provided critical intellectual input. CT supervised the study and edited the final manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by the German Research Foundation (DFG; Ta434/5-1 and SFB/TRR57).

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study protocol was approved by the local ethics committee and conducted in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki (ethics committee of the University Hospital Aachen, RWTH-University, Aachen, Germany, reference number BK 150/06). We secured written informed consent from the patient, the spouse or the legal guardian according to the German civil code BGB §1896.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Medical Care Center, Dr. Stein and Colleagues, Tomphecke 45, 41169 Mönchengladbach, Germany. 2 Department of Medicine III, RWTH-University Hospital Aachen, Aachen, Germany. 3 Section of Gastroenterology and Hepatology, Department of Internal Medicine, Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands. 4 Institute of Molecular Pathobiology, Experimental Gene Therapy and Clinical Chemistry, RWTH-University Hospital Aachen, Aachen, Germany. 5 Department of Hepatology and Gastroenterology, Charité University Medical Center, Berlin, Germany.

Received: 31 May 2019 Accepted: 4 December 2019
Published online: 12 December 2019

References
1. Volpe M. Natriuretic peptides and cardio-renal disease. Int J Cardiol. 2014;176(2):630–9.
2. Woodward GE, Rosado JA. Natriuretic peptides in vascular physiology and pathology. Int Rev Cell Mol Biol. 2008;268:59–93.
3. Bie P. Natriuretic peptides and normal body fluid regulation. Compr Physiol. 2018;8(3):1211–49.
4. Fu S, Ping P, Wang F, Luo L. Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure. J Biol Eng. 2018;12:2.
5. Wong PC, Guo J, Zhang A. The renal and cardiovascular effects of natriuretic peptides. Adv Physiol Educ. 2017;41(2):179–85.
6. Edwards BS, Zimmerman RS, Schwab TR, Heublein DM, Burnett JC Jr. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res. 1988;62(2):191–5.
7. Vesely DL. Atrial natriuretic peptide prohormone gene expression: hormones and diseases that upregulate its expression. IUBMB Life. 2002;53(3):153–9.
8. Lipinska-Gediga M, Mierzchala M, Durek G. Pro-atrial natriuretic peptide (pro-ANP) level in patients with severe sepsis and septic shock: prognostic and diagnostic significance. Infection. 2012;40(3):303–9.
9. Wühlert R. Science review: natriuretic peptides in critical illness. Crit Care. 2004;8(5):342–9.
10. Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem. 2004;50(1):234–6.
11. Morgenthaler NG, Struck J, Christ-Crain M, Bergmann A, Müller B. Pro-atrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: an observational study. Crit Care. 2005;9(1):R37–45.
12. Lee CS, Tkacs NC. Current concepts of neurohormonal activation in heart failure: mediators and mechanisms. AACN Adv Crit Care. 2008;19(4):364–85.
13. Pandey KN. Emerging roles of natriuretic peptides and their receptors in pathophysiology of hypertension and cardiovascular regulation. J Am Soc Hypertens. 2008;2(4):210–26.
14. Theilig F, Wu Q. ANP-induced signaling cascade and its implications in renal pathophysiology. Am J Physiol Renal Physiol. 2015;308(10):F1047–55.
15. Buckley MG, Marcus NJ, Yacoub MH. Cardiac peptide stability, aprotinin and room temperature: importance for assessing cardiac function in clinical practice. Clin Sci. 1999;97(6):689–95.
16. Seidler T, Pemberton C, Yandle T, Espiner E, Nicholls G, Richards M. The amino terminal regions of proBNP and proANP oligomerise through leucine zipper-like coiled-coil motifs. Biochem Biophys Res Commun. 1999;255(2):495–501.
17. Baertschi AJ, Monnier D, Schmidt U, Levitan ES, Fakan S, Roatti A. Acid prohormone sequence determines size, shape, and docking of secretory vesicles in atrial myocytes. Circ Res. 2001;89(3):E23–9.
18. Cappellini E, Gatti R, Spinella P, De Palo CB, Woloszczuk W, Maragno I, De Palo EF. Plasma atrial natriuretic peptide (ANP) fragments proANP (1–30) and proANP (31–67) measurements in chronic heart failure: a useful index for heart transplantation? Clin Chim Acta. 2001;303(1):49–52.

19. de Bold AJ, Borestein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Reprinted from Life Sci. 288–94, 1981. J Am Soc Nephrol. 2001;12(2):403–9; (discussion 403–8, 408–9).

20. Wiedermann CJ, Niederwürmbichler M, Braunsteiner H, Wiedermann CJ. Priming of polymorphonuclear neutrophils by atrial natriuretic peptide in vitro. J Clin Invest. 1992;90(5):1580–6.

21. Fujita S, Shimojo N, Terasaki F, Otuska K, Hosotani N, Kohda Y, Tanaka T, Nishio K, Yoshida T, Hiroe M, et al. Atrial natriuretic peptide exerts protective action against angiotensin II-induced cardiac remodeling by attenuating inflammation via endothelin-1/endothelin receptor a cascade. Heart Vessels. 2013;28(5):646–57.

22. Vollmar AM. The role of atrial natriuretic peptide in the immune system. Peptides. 2005;26(9):1086–94.

23. Moro C, Lafontan M. Natriuretic peptides and CGMP signaling control of energy homeostasis. Am J Physiol Heart Circ Physiol. 2013;304(3):H358–68.

24. Sengenès C, Berlan M, De Glisezinski I, Lafontan M, Galitzky J. Natriuretic peptides: a new lipidolytic pathway in human adipocytes. FASEB J. 2002;16(11):1345–51.

25. Tsukamoto O, Fujita M, Kato M, Yamazaki S, Asano Y, Ogi A, Okazaki H, Asai M, Nagamachi Y, Maeda N, et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. Am J Cardiol. 2006;93(22):2070–7.

26. Birkenfeld AL, Boschmann M, Englisch M, Moro C, Arafat AM, Luft FC,Jordan J. Atrial natriuretic peptide and adiponectin interactions in man. PLoS ONE. 2012;7(8):e43238.

27. Birkenfeld AL, Boschmann M, Jordan J. Metabolic regulation: effects of natriuretic peptide interactions. Expert Rev Endocrinol Metab. 2007;2(5):607–14.

28. Mazul-Sunko B, Zarkovic N, Vrkic N, Klinger R, Peric M, Bekavac-Beslin M, Matthes M, Luedde T, Trautwein C, Tacke F. Elevated asymmetric dimethylarginine in critically ill patients. Blood. 2007;110(17):5427–30.

29. Berendes E, Van Aken H, Raufhaake C, Schmidt C, Assmann G, Walter M. Differential secretion of atrial and brain natriuretic peptide in critically ill patients. Anesth Analg. 2001;93(3):676–82.

30. Alipoor E, Mohammad Hosseinzadeh F, Hosseinzadeh-Attar MJ. Adiponectin in critically ill patients: 'a novel marker for the prediction of cardiac depression in septic patients. J Endocrinol Invest. 2001;24(7):RC22–4.

31. Robinson K, Prins J, Venkatesh B. Clinical review: adiponectin biology and correlation with organ function, metabolism and inflammation. Crit Care. 2010;14(5):R179.

32. Koch A, Sanson E, Voigt S, Helm A, Trautwein C, Tacke F. Serum adiponectin upon admission to the intensive care unit may predict mortality in critically ill patients. J Crit Care. 2011;26(2):166–74.

33. Koch A, Sanson E, Helm A, Voigt S, Trautwein C, Tacke F. Regulation and prognostic relevance of serum ghrelin concentrations in critical illness and sepsis. Crit Care. 2010;14(3):R94.

34. Koch A, Gressner OA, Sanson E, Tacke F, Trautwein C. Serum resistin levels in critically ill patients are associated with inflammation, organ dysfunction and metabolism and may predict survival of non-septic patients. Crit Care. 2009;13(3):R95.

35. Rhodes A, Alhazzani W, Bellomo R, Chiumello D, Girard T, Greisen G, Kellum J, Marmont M, Torres A, et al. The Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304–77.

36. Oliver PM, Fox JE, Kim R, Rockman HA, Kim HS, Reddick RL, Pandey KN, Milgram SL, Smithies O, Maeda N. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci U S A. 1997;94(26):14730–5.

37. Vellaichamy E, Kaur K, Pandey KN. Enhanced activation of pro-inflammatory cytokines in mice lacking natriuretic peptide receptor A. Peptides. 2007;28(4):893–9.

38. Salomaa V, Hauvalinna A, Saarela O, Zeller T, Joussilhat P, Julia A, Muenzel T, Aromaa A, Evans A, Kusalaama K, et al. Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS ONE. 2016(4):e0110010.

39. Odermatt J, Hersberger L, Bolliger R, Graefel R, Christ-Crain M, Briol M, Bucher HC, Mueller B, Schuetz P. The natriuretic peptide MR-proANP predicts all-cause mortality and adverse outcome in community patients: a 10-year follow-up study. Clin Chem Lab Med. 2017;55(9):1407–16.

40. Rubanu S, Sciarretta S, Ciavraella GM, Venturinelli V, De Padis P, Tocci G, De Baise L, Ferrucci A, Volpe M. Reduced levels of N-terminal proatrial natriuretic peptide in hypertensive patients with metabolic syndrome and their relationship with left ventricular mass. J Hypertens. 2007;25(4):833–9.

41. Tsai S, Clemente-Casaes X, Revelo XS, Winer S, Winer DA. Are obesity-related insulin resistance and type 2 diabetes autoimmune diseases? Diabetes. 2015;64(6):1886–97.

42. de Bold AJ. Cardiac natriuretic peptides gene expression and secretion in inflammation. J Invest Med. 2009;57(1):29–32.

43. Dieppling B, Mueller T, Kollers B, Struck J, Ritze E, von Eckardstein A, Halmayer M, Kronenberg F. Pro-A-type natriuretic peptide and pro-adenomedinulin predict progression of chronic kidney disease: the MMMD Study. Kidney Int. 2009;75(4):408–14.

44. Gehebhuber A, Struck J, Poelz W, Pacher R, Morgenthaler NG, Bergmann A, Halmayer M, Mueller T. Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: comparison with B-type natriuretic peptide (BNP) and amino-terminal proBNP. Clin Chem. 2006;52(5):827–31.

45. Hicks CW, Engineer RS, Benoit JL, Dasarathy S, Christenson RH, Peacock WF. Procalcitonin as a biomarker for early sepsis in the emergency department. Eur J Emerg Med. 2014;21(2):112–7.

46. Guanand-Barber S, Grabin S, Chenevier-Gobeaux C, Quinquis L, Schmidt J, Kirzeg Z, Guerin S, Hausfater P, Bernot B, Brun P, et al. Is mid-regional atrial natriuretic peptide (MRproANP) an accurate marker of bacteremia in pylonephritis? Biomarkers. 2011;16(4):355–63.

47. Boeck L, Eggimann P, Smyrnios N, Paerger H, Thakkar N, Siegemund M, Marsch S, Rakic J, Tamm M, Stolz D. Midregional pro-Atrial natriuretic peptide and procalcitonin improve survival prediction in VAP. Eur Respir J. 2011;37(3):595–603.

48. Vazquez M, Jockers K, Christ-Crain M, Zimmerli W, Muller B, Schuetz P. MR-pro-atrial natriuretic peptide (MR-proANP) predicts short- and long-term outcomes in respiratory tract infections: a prospective validation study. Int J Cardiol. 2012;156(1):16–22.

49. Guignant C, Venet F, Voisin N, Poitevin F, Malcus C, Bohé J, Lepea P, Monneret G. Proatrial natriuretic peptide is a better predictor of 28-day mortality in septic shock patients than proendothelin-1. Crit Care. 2011;14(1):R5.

50. de Bold AJ. Cardiac natriuretic peptides gene expression and secretion in inflammation. J Invest Med. 2009;57(1):29–32.

51. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304–77.

52. Koch A, Voigt S, Helm A, Trautwein C, Tacke F. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care. 2011;15(1):R63.

53. Koch A, Weiskirchen R, Zimmermann HW, Sanson E, Trautwein C, Tacke F. Circulating retinol binding protein 4 in critically ill patients before specific treatment: prognostic impact and correlation with organ function, metabolism and inflammation. Crit Care. 2010;14(5):R179.
58. Asferg CL, Nielsen SJ, Andersen UB, Linneberg A, Møller DV, Hedley PL, Christiansen M, Gøtze JP, Jeppesen JL. Metabolic rather than body composition measurements are associated with lower serum natriuretic peptide concentrations in normal weight and obese men. Am J Hypertens. 2014;27(4):620–7.

59. Asferg CL, Nielsen SJ, Andersen UB, Linneberg A, Goetze JP, Jeppesen JL. Serum proatrial natriuretic peptide concentrations during oral glucose-induced acute hyperinsulinemia in lean and obese men. Peptides. 2019;111:98–102.

60. Asferg CL, Andersen UB, Linneberg A, Goetze JP, Jeppesen JL. Obese hypertensive men have lower circulating proatrial natriuretic peptide concentrations despite greater left atrial size. Am J Hypertens. 2019;31(6):645–50.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.